Bukwang Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Bukwang Pharmaceutical has a total shareholder equity of ₩229.0B and total debt of ₩78.9B, which brings its debt-to-equity ratio to 34.4%. Its total assets and total liabilities are ₩348.8B and ₩119.8B respectively.
Key information
34.4%
Debt to equity ratio
₩78.87b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩117.60b |
| Equity | ₩228.97b |
| Total liabilities | ₩119.83b |
| Total assets | ₩348.80b |
Recent financial health updates
Bukwang Pharmaceutical (KRX:003000) Has Debt But No Earnings; Should You Worry?
Nov 13
Is Bukwang Pharmaceutical (KRX:003000) Weighed On By Its Debt Load?
May 22Is Bukwang Pharmaceutical (KRX:003000) A Risky Investment?
Feb 10Recent updates
Bukwang Pharmaceutical (KRX:003000) Has Debt But No Earnings; Should You Worry?
Nov 13Is Bukwang Pharmaceutical (KRX:003000) Weighed On By Its Debt Load?
May 22Investors In Bukwang Pharmaceutical Co., Ltd. (KRX:003000) Should Consider This, First
Apr 03Did Bukwang Pharmaceutical's (KRX:003000) Share Price Deserve to Gain 71%?
Mar 08Is Bukwang Pharmaceutical (KRX:003000) A Risky Investment?
Feb 10How Much Of Bukwang Pharmaceutical Co., Ltd. (KRX:003000) Do Insiders Own?
Jan 14Does It Make Sense To Buy Bukwang Pharmaceutical Co., Ltd. (KRX:003000) For Its Yield?
Dec 19Did You Miss Bukwang Pharmaceutical's (KRX:003000) 90% Share Price Gain?
Nov 23Financial Position Analysis
Short Term Liabilities: A003000's short term assets (₩195.1B) exceed its short term liabilities (₩28.5B).
Long Term Liabilities: A003000's short term assets (₩195.1B) exceed its long term liabilities (₩91.3B).
Debt to Equity History and Analysis
Debt Level: A003000 has more cash than its total debt.
Reducing Debt: A003000's debt to equity ratio has increased from 0% to 34.4% over the past 5 years.
Debt Coverage: A003000's debt is well covered by operating cash flow (51.3%).
Interest Coverage: Insufficient data to determine if A003000's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 08:07 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bukwang Pharmaceutical Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Kyun Lim | IBK Securities Co. Ltd. |
| JongHoon Lee | Mirae Asset Securities Co., Ltd. (Pre-Merger) |
| Seung Kim | Samsung Securities Co. Ltd. |